MA43826B1 - Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation - Google Patents
Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisationInfo
- Publication number
- MA43826B1 MA43826B1 MA43826A MA43826A MA43826B1 MA 43826 B1 MA43826 B1 MA 43826B1 MA 43826 A MA43826 A MA 43826A MA 43826 A MA43826 A MA 43826A MA 43826 B1 MA43826 B1 MA 43826B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- menin
- pyrimidinic
- compounds
- mll
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101710169972 Menin Proteins 0.000 abstract 2
- 102100030550 Menin Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309372P | 2016-03-16 | 2016-03-16 | |
| PCT/US2017/022564 WO2017161028A1 (en) | 2016-03-16 | 2017-03-15 | Substituted inhibitors of menin-mll and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43826A MA43826A (fr) | 2018-11-28 |
| MA43826B1 true MA43826B1 (fr) | 2023-07-31 |
Family
ID=62683542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43826A MA43826B1 (fr) | 2016-03-16 | 2017-03-15 | Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR107891A1 (es) |
| MA (1) | MA43826B1 (es) |
-
2017
- 2017-03-15 MA MA43826A patent/MA43826B1/fr unknown
- 2017-03-15 AR ARP170100642A patent/AR107891A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR107891A1 (es) | 2018-06-28 |
| MA43826A (fr) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3429591T2 (ro) | Derivați de tieno[2,3-d]pirimidină substituiți în calitate de inhibitori ai menin-MLL și procedee de utilizare | |
| MA53835A (fr) | Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires | |
| PH12018501955A1 (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| MA44322A (fr) | Compositions comprenant des souches bactériennes | |
| EA201990048A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИДИНИЛ-ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ СОЕДИНЕНИЯ | |
| MA52856B1 (fr) | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 | |
| MA39034A1 (fr) | Composés de quinoline sélectivement substitués | |
| MA42471A (fr) | Compositions comprenant des souches bactériennes | |
| EP4230627A3 (en) | Inhibitors of the menin-mll interaction | |
| PH12017502188A1 (en) | Methods and compositions for inhibiting the interaction of menin with mll proteins | |
| MA43603A1 (fr) | Récepteurs chimériques et leurs procédés d'utilisation | |
| MA38183A1 (fr) | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| MA38347A1 (fr) | Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak) | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA39172B1 (fr) | Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines | |
| MA40219B1 (fr) | Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| EA202091708A1 (ru) | Ингибиторы днк-пк | |
| MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA44656B1 (fr) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1 | |
| MA38654B1 (fr) | Dérivés de type promédicament de triazolopyridines substituées | |
| MA43826B1 (fr) | Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation | |
| MA35064B1 (fr) | Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie | |
| MA46415B1 (fr) | Complexe et compositions pour le traitement de maladies ophtalmiques et dermatologiques |